Wilkes M S, Doblin B H, Shapiro M F
UCLA School of Medicine.
Ann Intern Med. 1992 Jun 1;116(11):912-9. doi: 10.7326/0003-4819-116-11-912.
To assess both the accuracy of scientific data presented in print pharmaceutical advertisements and the compliance of these advertisements with current Food and Drug Administration (FDA) standards.
Cross-sectional survey.
Each full-page pharmaceutical advertisement (n = 109) appearing in 10 leading medical journals, along with all available references cited in the advertisement (82% of the references cited were available) were sent to three reviewers: two physicians in the relevant clinical area who were experienced in peer review and one academic clinical pharmacist. Reviewers, 95% of whom responded, were asked to evaluate the advertisements using criteria based on FDA guidelines, to judge the educational value and overall quality of the advertisements, and to make a recommendation regarding publication.
In 30% of cases, two or more reviewers disagreed with the advertisers' claim that the drug was the "drug of choice." Reviewers felt that information on efficacy was balanced with that on side effects and contraindications in 49% of advertisements but was not balanced in 40%. Reviewers agreed with advertisements' claims that the drug was safe in 86% of the cases but judged that headlines in 32% of the advertisements containing headlines misled the reader about efficacy. In 44% of cases, reviewers felt that the advertisement would lead to improper prescribing if a physician had no other information about the drug other than that contained in the advertisement. Fifty-seven percent of advertisements were judged by two or more reviewers to have little or no educational value. Overall, reviewers would not have recommended publication of 28% of the advertisements and would have required major revisions in 34% before publication.
In the opinion of the reviewers, many advertisements contained deficiencies in areas in which the FDA has established explicit standards of quality. New strategies are needed to ensure that advertisements comply with standards intended to promote proper use of the products and to protect the consumer.
评估印刷药品广告中所呈现科学数据的准确性以及这些广告是否符合美国食品药品监督管理局(FDA)现行标准。
横断面调查。
选取10种主要医学期刊上刊登的每一则整版药品广告(n = 109),连同广告中引用的所有可获取参考文献(所引用参考文献的82%可获取),发送给三位评审人员:两位相关临床领域经验丰富的同行评审医师和一位学术临床药剂师。95%做出回应的评审人员被要求根据FDA指南中的标准评估广告,判断广告的教育价值和整体质量,并就是否发表提出建议。
在30%的案例中,两名或更多评审人员不同意广告商称该药物为“首选药物 ”的说法。评审人员认为,49%的广告中关于疗效的信息与副作用和禁忌症的信息是平衡的,但40%并非如此。在86%的案例中,评审人员认同广告中称该药物安全的说法,但认为32%带有标题的广告中的标题在疗效方面误导了读者。在44%的案例中,评审人员认为,如果医生除了广告中包含的药物信息外没有其他关于该药物的信息,那么该广告会导致不恰当的处方。两名或更多评审人员判定57%的广告几乎没有或完全没有教育价值。总体而言,评审人员不会推荐发表28%的广告,并且在发表前会要求对34%的广告进行重大修改。
评审人员认为,许多广告在FDA已制定明确质量标准的领域存在缺陷。需要新的策略来确保广告符合旨在促进产品合理使用和保护消费者的标准。